Among other things, the report found that providers incur additional costs associated with delivering clotting factor that are not separately reimbursed by Medicare. Specifically, the report cited delivery costs generated in inventory management, specialized refrigerated storage, shipping, and the provision of ancillary supplies such as needles, syringes, and tourniquets to patients that were not accounted for by Medicare payment for the clotting factor product alone
Patients who use nicotine products may not experience the swelling, redness or bleeding that typically accompanies the initial stages of gum disease
Biesbroek G, Sanders EA, Roeselers G, Wang X, Caspers MP, Trzcinski K, et al
As noted previously, under this scenario, given that there is no additional rebate amount due upon reconciliation compared to the rebate amount stated on the Rebate Report, there would not be a civil money penalty assessed on the reconciled rebate amount